Replies to post #236821 on Biotech Values

[DewDiligence]

EXEL—(-20%)—misses_OS_endpt_in_phase-3_HCC_trial:

https://finance.yahoo.com/news/exelixis-ipsen-announce-cabozantinib-combination-050000313.html

Exelixis, Inc. and Ipsen today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC), met one of the primary endpoints, demonstrating significant improvement in progression-free survival (PFS) at the planned primary analysis.

A prespecified interim analysis for the second primary endpoint of overall survival (OS), conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination of cabozantinib and atezolizumab but did not reach statistical significance. Based on the preliminary OS data, Exelixis anticipates that the probability of reaching statistical significance at the time of the final analysis is low.

Ipsen (IPN.PA) is -5% today.